Marshall Wace North America’s Immunogen Inc IMGN Stock Holding History

Marshall Wace North America’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-32,569	Closed	-$264K	–	1871
2021 Q1	$264K	Sell	32,569 -1,542,169	-98%	-$12.6M	﹤0.01%	1348
2020 Q4	$10.2M	Buy	+1,574,738	New	+$9.18M	0.05%	376
2019 Q2	–	Sell	-19,047	Closed	-$52K	–	1718
2019 Q1	$52K	Buy	+19,047	New	+$82.5K	﹤0.01%	1262
2018 Q4	–	Sell	-427,000	Closed	-$4.04M	–	1684
2018 Q3	$4.04M	Buy	+427,000	New	+$4.1M	0.03%	359
2018 Q2	–	Sell	-110,209	Closed	-$1.16M	–	1775
2018 Q1	$1.16M	Buy	+110,209	New	+$1.09M	0.01%	955
2017 Q3	–	Sell	-77,315	Closed	-$541K	–	1561
2017 Q2	$541K	Buy	+77,315	New	+$354K	﹤0.01%	1077

Other funds holding IMGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Marshall Wace North America's IMGN Position: Q2 2021 in Review

Marshall Wace North America sold out of Immunogen Inc (IMGN) in Q2 2021, closing a stake of 32,569 shares — an estimated $264K sold.

Marshall Wace North America first reported a position in IMGN in Q2 2017 and held it in 6 quarters. The position peaked at $10.2M in Q4 2020. 214 funds tracked by Wall St. Rank hold IMGN as of Q2 2021.

Marshall Wace North America reported no remaining Immunogen Inc position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 32,569 Immunogen Inc shares in Q2 2021, an estimated $264K.
Marshall Wace North America first reported a position in Immunogen Inc in Q2 2017 and held it in 6 quarters.
Marshall Wace North America's Immunogen Inc position peaked at $10.2M in Q4 2020.
214 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.